UBS Group’s Decoy Therapeutics DCOY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $180 | Sell |
25
-521
| -95% | -$3.21K | ﹤0.01% | 10023 |
|
|
2026
Q1 | $3.57K | Buy |
546
+136
| +33% | +$1.17K | ﹤0.01% | 9064 |
|
|
2025
Q4 | $3.19K | Buy |
410
+408
| +20,400% | +$10.6K | ﹤0.01% | 9082 |
|
|
2025
Q3 | $106 | Sell |
2
-99
| -98% | -$9.13K | ﹤0.01% | 9908 |
|
|
2025
Q2 | $16.3K | Sell |
101
-87
| -46% | -$12.2K | ﹤0.01% | 8577 |
|
|
2025
Q1 | $25.5K | Buy |
188
+149
| +382% | +$43.4K | ﹤0.01% | 8057 |
|
|
2024
Q4 | $13K | Buy |
39
+38
| +3,800% | +$10.4K | ﹤0.01% | 8168 |
|
|
2024
Q3 | $375 | Hold |
1
| – | – | ﹤0.01% | 8971 |
|
|
2024
Q2 | $269 | Buy |
+1
| New | +$661 | ﹤0.01% | 9019 |
|
|
2024
Q1 | – | Hold |
0
| – | – | – | 9098 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 8993 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 8998 |
|
|
2023
Q2 | – | Sell |
-1
| Closed | -$2.29K | – | 8484 |
|
|
2023
Q1 | $2.15K | Buy |
+1
| New | +$3.22K | ﹤0.01% | 8565 |
|
|
2022
Q4 | – | Sell |
-1
| Closed | -$3.55K | – | 10221 |
|
|
2022
Q3 | $8K | Hold |
1
| – | – | ﹤0.01% | 8749 |
|
|
2022
Q2 | $9K | Buy |
+1
| New | +$8.63K | ﹤0.01% | 8167 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 9921 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 10033 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 8328 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 8350 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 7444 |
|
|
2020
Q2 | – | Hold |
0
| – | -$8K | – | 8321 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 7088 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 7762 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 6835 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 8128 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 8122 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 7103 |
|
|
2018
Q3 | – | Hold |
0
| – | -$1K | – | 8242 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 7836 |
|
|
2018
Q1 | – | Hold |
0
| – | -$7K | – | 8130 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 7240 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 7157 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6606 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6216 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6986 |
|
|
2016
Q3 | – | Hold |
0
| – | -$21K | – | 7906 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6270 |
|
|
2016
Q1 | – | Hold |
0
| – | -$17K | – | 8112 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6909 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6292 |
|
|
2015
Q2 | – | Hold |
0
| – | -$24K | – | 8787 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 6799 |
|
Other funds holding DCOY
UBS Group's DCOY Position: Q2 2026 in Review
UBS Group reduced its Decoy Therapeutics (DCOY) stake by 95% in Q2 2026, selling an estimated $3.21K and leaving 25 shares worth $180. The position accounts for ﹤0.01% of the portfolio, ranked #10023.
UBS Group first reported a position in DCOY in Q2 2022 and has held it in 12 quarters since. The position peaked at $25.5K in Q1 2025. 4 funds tracked by Wall St. Rank hold DCOY as of Q2 2026.
- UBS Group held 25 shares of Decoy Therapeutics worth $180 as of Q2 2026.
- UBS Group sold 521 Decoy Therapeutics shares in Q2 2026, an estimated $3.21K.
- Decoy Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10023 holding.
- UBS Group first reported a position in Decoy Therapeutics in Q2 2022 and has held it in 12 quarters since.
- UBS Group's Decoy Therapeutics position peaked at $25.5K in Q1 2025.
- 4 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.